Barclays Remains a Buy on Medline (MDLN)
In a report released yesterday, Glen Santangelo from Barclays reiterated a Buy rating on Medline. The company’s shares closed yesterday at $42.16.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Santangelo covers the Healthcare sector, focusing on stocks such as Align Tech, Cencora, and Cardinal Health. According to TipRanks, Santangelo has an average return of 4.7% and a 50.18% success rate on recommended stocks.
Currently, the analyst consensus on Medline is a Strong Buy with an average price target of $52.35, implying a 24.17% upside from current levels. In a report released on March 16, TipRanks – PerPlexity also initiated coverage with a Buy rating on the stock with a $48.00 price target.
Based on Medline’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $7.79 billion and a net profit of $180 million.
Based on the recent corporate insider activity of 62 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MDLN in relation to earlier this year. Most recently, in December 2025, Carlyle Group L.P., a Major Shareholder at MDLN sold 19,136,333.00 shares for a total of $554,953,657.00.
Read More on MDLN:
